Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority

 
• By Joseph Haas
  
Glaucoma model
Nicox is looking to enter the very competitive glaucoma therapeutic space • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D